IntrinsicIntrinsic
← All summaries

BIOMERICA INC

BMRA
Financials & Chart →

Business Summary

Biomerica, Inc. operates as a global biomedical technology company that develops, patents, manufactures, and markets advanced diagnostic and therapeutic products. The company's diagnostic test kits analyze blood, urine, nasal, or fecal material to aid in diagnosing diseases, food intolerances, and other medical conditions, detecting specific bacteria, hormones, antibodies, antigens, and other substances at extremely low concentrations. The industry is characterized by technological advances that have enabled diagnostic tests to be performed not only in clinical laboratories but also at home and at the point-of-care in physicians' offices. The company believes its rapid point-of-care tests, when properly used, can be as accurate as laboratory tests. The competitive landscape is shaped by product uniqueness, technology, quality, performance, pricing, and service, with the industry experiencing a noticeable trend toward consolidation.

The company's competitors include divisions and subsidiaries of well-established medical and pharmaceutical companies that are much larger than Biomerica and expend substantially greater amounts for research and development, manufacturing, advertising, and marketing. The company offers several proprietary products with notable competitive advantages, including EZ Detect colon disease home test, Aware Breast Self-Exam product, inFoods® IBS product, and hp+detect™ for H. pylori detection. The company believes its competitive position is strengthened by the distinctiveness of its product offerings, the quality and speed of its test results, and its patent portfolio, despite limited marketing resources. In contract development and manufacturing services, the company competes on the basis of technical capabilities, quality, pricing, service, and project execution.

The company generates revenue primarily through the sale of diagnostic test kits worldwide, mainly to clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties that utilize the technology underlying its products. Additionally, the company is commercializing its inFoods® IBS product through physician-directed and laboratory-based channels, including third-party reimbursement pathways. The business model includes a mix of transactional product sales and service-based revenue, with a significant portion of revenues derived from international sales. The company's business model for inFoods® IBS includes the potential out-licensing of the product and related patents to a large international life sciences or technology company.

The company's product portfolio includes diagnostic test kits for clinical laboratories, over-the-counter home use, and physicians' office settings. For the fiscal year ended May 31, 2026, clinical lab sales were $2,732,000, contract manufacturing was $891,000, over-the-counter sales were $821,000, and physician's office sales were $9,000. The inFoods® IBS product utilizes a simple blood test to identify patient-specific foods that, when eliminated from the diet, may help reduce IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. The hp+detect™ test is a proprietary diagnostic test for detecting Helicobacter pylori and monitoring treatment, which received FDA clearance in December 2023 and received registration from the UK MHRA in February 2026.

The company's research and development efforts have led to the FDA 510(k) clearance of hp+detect™, a proprietary diagnostic test for detecting Helicobacter pylori and monitoring treatment. The company has launched its inFoods® IBS product, which leverages patented diagnostic-guided therapy technology. During fiscal 2026, the company received its first commercial order for hp+detect™ from one of the largest clinical laboratory chains operating across Europe, for the United Kingdom market. The company also entered into a marketing services agreement with Henry Schein to support the introduction and commercialization of inFoods® IBS to physicians in the United States. In May 2026, the company entered into a Master Services Agreement with a life sciences company for the development of proprietary in vitro diagnostic assays, with an initial contract development target fee of over $1,750,000.

For the fiscal year ended May 31, 2026, net sales were approximately $4,453,000, a decrease of $858,000, or 16%, compared to $5,311,000 for the fiscal year ended May 31, 2025. The decrease was primarily attributable to lower clinical laboratory sales, reduced over-the-counter sales, and lower contract manufacturing revenue, partially offset by increased demand for the inFoods® IBS product. Consolidated cost of sales was approximately $4,091,000, or 92% of net sales, compared to $4,813,000, or 91% of net sales, in the prior year. The company raised approximately $1,827,000 in net proceeds under its ATM offering program during fiscal 2026, and net cash used in operating activities improved by approximately 11% to approximately $3,421,000.

The company has a history of operating losses and negative cash flows from operations, and its current level of cash and cash equivalents is not sufficient to meet its operating plans for the next 12 months, raising substantial doubt about its ability to continue as a going concern. As of May 31, 2026, the company had cash and cash equivalents of approximately $1,308,000 and working capital of approximately $1,535,000. The company's future viability depends on obtaining additional financing, achieving further operating efficiencies, increasing sales, reducing costs, and ultimately generating profitable operations.

Business Outlook

A key growth vector is the inFoods® IBS product, which the company is commercializing through physician-directed and laboratory-based channels. The Centers for Medicare & Medicaid Services established a national Medicare payment rate of $300 for the test effective January 1, 2026, and the applicable Medicare Administrative Contractor confirmed that claims may be considered on an individual, claim-by-claim basis. The company entered into a marketing services agreement with Henry Schein to support the introduction and commercialization of inFoods® IBS to physicians in the United States. Following fiscal year-end, the partner lab began submitting initial Medicare claims, and initial valid claims submitted to date have been paid at the full CMS price of $300. The company is also evaluating distribution, partnership, and licensing opportunities with U.S. companies to support a scalable, broader market launch, and may pursue reimbursement with private payer insurance companies over time.

Another growth vector is the hp+detect™ test for H. pylori detection, which received FDA clearance in December 2023 and registration from the UK MHRA in February 2026. During fiscal 2026, the company received its first commercial order for hp+detect™ from a large clinical laboratory chain for the United Kingdom market. The company continues to market hp+detect™ to laboratories in the United States and Europe and pursue opportunities for broader commercial adoption. Additionally, the company is pursuing contract development and manufacturing opportunities, including a Master Services Agreement entered into in May 2026 with a life sciences company for the development of proprietary in vitro diagnostic assays, with an initial contract development target fee of over $1,750,000, to be earned on a milestone-completion basis over an estimated 19 to 25 months period.

The company's margin and cost outlook is influenced by its efforts to manage operating expenses and improve cost absorption. Cost of sales as a percentage of net sales increased modestly to 92% in fiscal 2026 from 91% in fiscal 2025, primarily due to changes in product mix and lower overall sales volume, which resulted in reduced absorption of fixed manufacturing costs. The company believes increased sales volumes, including from inFoods® IBS and contract manufacturing activities, could provide greater utilization of its existing manufacturing infrastructure and improved absorption of fixed production costs. Total operating expenses increased approximately 1% during fiscal 2026 compared with fiscal 2025, while net cash used in operating activities improved by approximately 11%.

The company's operational outlook includes a focus on alternative manufacturing and shipping strategies through BioEurope GmbH and Biomerica de Mexico to mitigate risks from tariffs and trade policies. The company is implementing contingency plans, including alternative sourcing strategies and supplier diversification, to support supply chain continuity. The company maintains manufacturing and assembly operations in Mexicali, Mexico, and operates BioEurope GmbH in Europe for sales and distribution. As of May 31, 2026, the company employed a total of 50 employees in the United States, Mexico, UK, and Germany, of which 50 were full-time employees.

The company's capital allocation strategy includes continued investment in research and development, with consolidated research and development expenses totaling approximately $788,000 for the fiscal year ended May 31, 2026, compared to $1,023,000 in the prior year. The company raised approximately $1,827,000 in net proceeds under its ATM offering program during fiscal 2026. The company has not paid any cash dividends on its common stock in the past and does not plan to pay any cash dividends in the foreseeable future, intending to retain any earnings to finance the continued operation and expansion of its business. The company also entered into a Securities Purchase Agreement on May 29, 2026, to sell its investment in Diagnosis S.A. for an aggregate purchase price of $500,000, with the purchasers advancing the purchase price in exchange for a secured promissory term note bearing interest at 8% per annum.

A significant headwind is the company's going concern status, as its current cash and cash equivalents are insufficient to meet its operating plans for the next 12 months. The company's ability to continue as a going concern depends on obtaining additional financing, achieving further operating efficiencies, increasing sales, reducing costs, and ultimately generating profitable operations. The company faces risks related to its reliance on a limited number of key distributors, with its largest distributor accounting for 31% of net sales in each of fiscal 2026 and 2025, and three and four distributors accounting for 59% and 69% of gross accounts receivable as of May 31, 2026 and 2025, respectively.

The company faces headwinds from international trade and geopolitical risks, including tariffs, trade policies, and supply-chain disruptions, which could increase costs or delay shipments. The company also faces risks related to regulatory compliance, particularly with evolving EU IVDR requirements, which may increase compliance costs and extend certification timelines. The company's revenues have declined, and there is no assurance that this trend will reverse, with net sales decreasing from approximately $5,311,000 in fiscal 2025 to approximately $4,453,000 in fiscal 2026, a decline of approximately 16%.

Risk Factors

The company faces substantial doubt about its ability to continue as a going concern, as its current cash and cash equivalents of approximately $1,308,000 are insufficient to meet its operating plans for the next 12 months. The company has a history of operating losses and negative cash flows, with net sales declining approximately 16% from $5,311,000 in fiscal 2025 to $4,453,000 in fiscal 2026. The company relies on a limited number of key distributors, with its largest distributor accounting for 31% of net sales in each of fiscal 2026 and 2025, and three and four distributors accounting for 59% and 69% of gross accounts receivable as of May 31, 2026 and 2025, respectively. The company's international sales are subject to risks including tariffs, trade barriers, and geopolitical instability, with substantial sales to distributors in Asia and Europe. The company's ability to raise capital is constrained by SEC regulations limiting the amount it can sell under its shelf registration statement, with a public float of $9,174,674 and an offering limit of $3,058,225 as of August 28, 2026. The company's common stock is subject to potential delisting from Nasdaq if its Market Value of Listed Securities falls below $5 million for 30 consecutive business days, as per a new Nasdaq rule approved by the SEC on July 22, 2026.

Management Priorities

Management's message emphasizes disciplined capital management, with efforts to reduce research and development spending as certain development programs progressed toward commercialization, reallocating resources toward commercial, regulatory, and reimbursement activities, managing working capital, and maintaining disciplined capital expenditures. The company raised approximately $1,827,000 in net proceeds under its ATM offering program during fiscal 2026, providing additional liquidity. Management believes the diversified portfolio approach provides opportunities to generate revenue from existing business while advancing newer commercial initiatives, including inFoods® IBS and hp+detect™. Strategic priorities include continuing the phased commercialization of inFoods® IBS, pursuing distribution, partnership, and licensing opportunities, and actively exploring strategic opportunities to enhance and create shareholder value.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 7, MD&A — Results of Operations
  2. [2] Item 7, MD&A — Results of Operations
  3. [3] Item 7, MD&A — Results of Operations
  4. [4] Item 7, MD&A — Results of Operations
  5. [5] Item 7, MD&A — Results of Operations
  6. [6] Item 7, MD&A — Results of Operations
  7. [7] Item 7, MD&A — Results of Operations
  8. [8] Item 7, MD&A — Results of Operations
  9. [9] Item 7, MD&A — Results of Operations
  10. [10] Item 7, MD&A — Results of Operations
  11. [11] Item 7, MD&A — Results of Operations
  12. [12] Item 7, MD&A — Results of Operations
  13. [13] Item 7, MD&A — Results of Operations
  14. [14] Item 7, MD&A — Results of Operations
  15. [15] Item 7, MD&A — Results of Operations
  16. [16] Item 7, MD&A — Results of Operations
  17. [17] Item 7, MD&A — Results of Operations
  18. [18] Item 7, MD&A — Results of Operations
  19. [19] Item 7, MD&A — Results of Operations
  20. [20] Item 7, MD&A — Results of Operations
  21. [21] Item 7, MD&A — Results of Operations
  22. [22] Item 7, MD&A — Results of Operations
  23. [23] Item 7, MD&A — Results of Operations
  24. [24] Item 7, MD&A — Results of Operations
  25. [25] Item 7, MD&A — Results of Operations
  26. [26] Item 7, MD&A — Results of Operations
  27. [27] Item 7, MD&A — Results of Operations
  28. [28] Item 7, MD&A — Results of Operations
  29. [29] Item 7, MD&A — Results of Operations
  30. [30] Item 7, MD&A — Results of Operations
  31. [31] Item 7, MD&A — Results of Operations
  32. [32] Item 7, MD&A — Results of Operations
  33. [33] Item 7, MD&A — Results of Operations
  34. [34] Item 7, MD&A — Results of Operations
  35. [35] Item 7, MD&A — Results of Operations
  36. [36] Item 7, MD&A — Results of Operations
  37. [37] Item 7, MD&A — Results of Operations
  38. [38] Item 7, MD&A — Results of Operations
  39. [39] Item 7, MD&A — Results of Operations
  40. [40] Item 7, MD&A — Results of Operations
  41. [41] Item 7, MD&A — Results of Operations
  42. [42] Item 7, MD&A — Results of Operations
  43. [43] Item 7, MD&A — Results of Operations
  44. [44] Item 7, MD&A — Results of Operations
  45. [45] Item 7, MD&A — Results of Operations
  46. [46] Item 7, MD&A — Results of Operations
  47. [47] Item 7, MD&A — Results of Operations
  48. [48] Item 7, MD&A — Results of Operations
  49. [49] Item 7, MD&A — Results of Operations
  50. [50] Item 7, MD&A — Results of Operations
  51. [51] Item 7, MD&A — Results of Operations
  52. [52] Item 7, MD&A — Results of Operations
  53. [53] Item 7, MD&A — Results of Operations
  54. [54] Item 7, MD&A — Results of Operations
  55. [55] Item 7, MD&A — Results of Operations
  56. [56] Item 7, MD&A — Results of Operations
  57. [57] Item 7, MD&A — Results of Operations
  58. [58] Item 7, MD&A — Results of Operations
  59. [59] Item 7, MD&A — Results of Operations
  60. [60] Item 7, MD&A — Results of Operations
  61. [61] Item 7, MD&A — Results of Operations
  62. [62] Item 7, MD&A — Results of Operations
  63. [63] Item 7, MD&A — Results of Operations
  64. [64] Item 7, MD&A — Results of Operations
  65. [65] Item 7, MD&A — Results of Operations
  66. [66] Item 7, MD&A — Results of Operations
  67. [67] Item 7, MD&A — Results of Operations
  68. [68] Item 7, MD&A — Results of Operations
  69. [69] Item 7, MD&A — Results of Operations
  70. [70] Item 7, MD&A — Results of Operations
  71. [71] Item 7, MD&A — Results of Operations
  72. [72] Item 7, MD&A — Results of Operations
  73. [73] Item 7, MD&A — Results of Operations
  74. [74] Item 7, MD&A — Results of Operations
  75. [75] Item 7, MD&A — Results of Operations
  76. [76] Item 7, MD&A — Results of Operations
  77. [77] Item 7, MD&A — Results of Operations
  78. [78] Item 7, MD&A — Results of Operations
  79. [79] Item 7, MD&A — Results of Operations
  80. [80] Item 7, MD&A — Results of Operations
  81. [81] Item 7, MD&A — Results of Operations
  82. [82] Item 7, MD&A — Results of Operations
  83. [83] Item 7, MD&A — Results of Operations
  84. [84] Item 7, MD&A — Results of Operations
  85. [85] Item 7, MD&A — Results of Operations
  86. [86] Item 7, MD&A — Results of Operations
  87. [87] Item 7, MD&A — Results of Operations
  88. [88] Item 7, MD&A — Results of Operations
  89. [89] Item 7, MD&A — Results of Operations
  90. [90] Item 7, MD&A — Results of Operations
  91. [91] Item 7, MD&A — Results of Operations
  92. [92] Item 7, MD&A — Results of Operations
  93. [93] Item 7, MD&A — Results of Operations
  94. [94] Item 7, MD&A — Results of Operations
  95. [95] Item 7, MD&A — Results of Operations
  96. [96] Item 7, MD&A — Results of Operations
  97. [97] Item 7, MD&A — Results of Operations
  98. [98] Item 7, MD&A — Results of Operations
  99. [99] Item 7, MD&A — Results of Operations
  100. [100] Item 7, MD&A — Results of Operations

Analysis on 8/31/2026